Arca
Skip to content
Tools
Tools

S1PR4: Sphingosine 1-phosphate receptor 4

G protein-coupled receptor highly expressed in immune cells, where it regulates immune response and cytokine production.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on S1PR4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Etrasimod

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        EtrasimodApprovedPfizerSmall moleculeModulatorSphingosine 1-phosphate receptor Edg-6 modulator12

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCEtrasimodPhase 4Not yet recruitingSir Run Run Shaw HospitalAug 24, 2026
        A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative ColitisEtrasimodPhase 1Not yet recruitingHelixon Biotechnology (Suzhou) Co., LtdAug 17, 2026
        A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UCEtrasimod—Not yet recruitingTang-Du HospitalJul 15, 2026
        Etrasimod as Prevention of PouchitisEtrasimodPhase 2RecruitingMaia KayalMar 23, 2026
        A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisEtrasimodPhase 2RecruitingPfizerMar 13, 2026
        An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative ColitisEtrasimod—Active, not recruitingPfizerMar 10, 2026
        Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative ColitisEtrasimodNot applicableRecruitingShowa Inan General HospitalNov 24, 2025
        An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisEtrasimod—Active, not recruitingPfizerMay 3, 2024

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Hypothyroidism0.51
        • Thyroid gland disorder0.35
        • Autoimmune thyroid disease0.35
        • Kidney transplant0.34
        • Hashimoto thyroiditis0.29
        • Femur fracture0.26
        • Gallbladder disorder0.16

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3230, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O95977, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.